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Abstract: Thirteen mammalian aquaporin (AQP) water channels are known, and few of them play
a role in the mammalian reproductive system. In our earlier study, the predominance of AQP5 in the
late-pregnant rat uterus was proven. Our current aim was to investigate the effect of estrogen- and
gestagen-related compounds on the expression of the AQP5 channel in the late-pregnant rat uterus.
Furthermore, we examined the effect of hormonally-induced preterm delivery on the expression of
AQP5 in the uterus. We treated pregnant Sprague-Dawley rats subcutaneously with 17β-estradiol,
clomiphene citrate, tamoxifen citrate, progesterone, levonorgestrel, and medroxyprogesterone acetate.
Preterm delivery was induced by subcutaneous mifepristone and intravaginal prostaglandin E2.
Reverse-transcriptase PCR and Western blot techniques were used for the detection of the changes
in AQP5 mRNA and protein expressions. The amount of AQP5 significantly increased after
progesterone and progesterone analogs treatment on 18 and 22 days of pregnancy. The 17β-estradiol
and estrogen receptor agonists did not influence the AQP5 mRNA level; however, estradiol
induced a significant increase in the AQP5 protein level on the investigated days of gestation.
Tamoxifen increased the AQP5 protein expression on day 18, while clomiphene citrate was ineffective.
The hormonally-induced preterm birth significantly decreased the AQP5 level similarly to the day of
delivery. We proved that AQP5 expression is influenced by both estrogen and progesterone in the
late-pregnant rat uterus. The influence of progesterone on AQP5 expression is more predominant as
compared with estrogen.
Keywords: aquaporin 5; pregnancy; estrogen; gestagen
1. Introduction
Aquaporins (AQPs) are small hydrophobic integral membrane proteins which facilitate rapid
passive movement of water across the cell membrane [1]. To this day, thirteen AQP isoforms have
been identified in mammals, and twelve of them can be found in female and male reproductive
tissues in mice, rats, dogs, swine, and humans [2,3]. According to the coding sequence and the
permeability features, AQPs are divided into three major subtypes: classical AQPs, aquaglyceroporins,
and unorthodox aquaporins. AQP0, 1, 2, 4, 5, and 8 are classical AQPs which are water-selective
channels, while AQP3, 7, 9, and 10 can be classified as aquaglyceroporins and are permeable to glycerol,
urea, and other small solutes, as well as water [4,5]. AQP11 and 12 belong to the unorthodox aquaporin
group, the function of which has not been clearly identified [6,7].
AQPs have an essential role in the female reproductive system, and in the mammalian uterus
the AQP1, 2, 3, 4, 5, 7, 8, and 9 isoforms have been detected [2]. The AQP1, 2, 3, and 8 isoforms
might be involved in water movement during uterine imbibition, and they may play important
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roles in hormone-mediated water and other small molecule transport [8]. AQP8 knockout (KO)
pregnant mice had a significantly higher number of embryos, and fetal/neonatal weight and the
amount of amniotic fluid was greater compared to wild type controls [9]. Contrarily, the number of
embryos and the fetal weight decreased in AQP1-KOs. The AQP1-KO placenta demonstrated increased
degeneration with evidence of altered blood vessel structure and increased syncytiotrophoblast
nodules [10]. AQP5-KO female mice did not show any difference in conception and implantation
as compared with wild-type animals [11]. He et al. [12] found that AQP2 expression in human
endometrium correlates with serum 17β-estradiol and progesterone levels; therefore, it is menstrual
cycle-dependent. Former studies identified the estrogen response element in the promoter region
of the AQP2 and 5 genes, which provides the immediate regulation of these water channels by
estrogen [13,14]. Water channel regulation was also investigated in the uterus of cycling bitches, and it
was discovered that AQP5 was particularly expressed in response to high levels of progesterone [15].
Skowronska et al. [16] also investigated the changes of AQP5 expression due to progesterone and
estradiol treatments in an in vitro study on porcine uterus. They found that AQP5 gene expression
was down-regulated after the estrogen and progesterone treatments during the mid-luteal phase, but
during luteolysis, it was increased by estrogen. A recent experiment was carried out on ovariectomized
rats, and they received testosterone, estrogen, or a combination of them. This study determined
that testosterone enhanced the expression of AQP5 in the uterus, and this effect was diminished by
a following estrogen treatment [17]. They also observed the increase of AQP5 protein expression in
ovariectomized rat uterus in response to progesterone alone or in combination with estrogen [18].
It has been postulated that AQPs take part in the processes of fertilization, blastocyst formation,
and implantation [19]. AQP1 and 2 are the most concentrated in the endometrium at the time
of implantation, suggesting that they may have a physiological role in uterine receptivity [12,20].
Moreover, the cellular and subcellular localizations of amniotic AQPs indicate that the AQPs play
distinct functional roles, such as apoptosis for amniotic fluid homeostasis or the tissue remodeling of
amniotic membranes during pregnancy. It was proven that AQP1, 3, 8, 9, and 11 play crucial roles in
the transfer of water across the placenta [21].
In earlier studies, we determined the expression of AQP1, 2, 3, 5, 8, and 9 isoforms in the pregnant
rat uterus. We observed that AQP5 mRNA and protein expression showed the most significant
changes during pregnancy. AQP5 expression was the most remarkable on days 18–21 of pregnancy
and dramatically dropped on the last day (day 22) of gestation. We determined the effect of oxytocin on
the myometrial expression of AQP5. Our results led us to suppose that oxytocin selectively decreases
the expression of AQP5 at the end of pregnancy and may be of importance in the initiation of delivery
in rats [22].
It is well known that the expression of various AQPs can be regulated by steroid sex hormones [18,23]
in female reproductive tissues, but we have limited data concerning the expression of AQP5 under the
effect of female sexual hormones in the late-pregnant uterus and the delivery. The primary aim of this
study was to investigate the effects of estrogen and progesterone receptors agonists on the expression
of AQP5 in the late-pregnant rat uterus. We also wanted to investigate the alteration of uterine AQP5
expression during hormonally-induced preterm birth in rats.
2. Results
2.1. The Effects of Estrogen-Related Compounds on Aquaporin 5 (AQP5) Expression
We investigated the effect of 17β-estradiol on AQP5 expression on day 18 and 22 of pregnancy.
17β-estradiol pretreatment did not cause any significant changes in the AQP5 mRNA levels, either on
day 18 or day 22 of pregnancy compared to the control (Figure 1A). The protein expression of AQP5
significantly increased both on day 18 (p < 0.001) and day 22 (p < 0.001) of pregnancy, compared to the
non-treated control uterus (Figure 1B).
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Figure 1. Results of PCR and Western immunoblotting experiments after 17β-estradiol treatment. The 
changes of mRNA (A) and protein (B) expression of aquaporin 5 (AQP5) after 17β-estradiol (E) 
pretreatment in pregnant rat uterus on days 18 and 22. ns > 0.05, *** p < 0.001 as compared with the 
data on non-treated control uterus. Each bar denotes the mean ± S.D. n = 6. The bands resulting from 
non-specific bindings of the polyclonal AQP5-antibody were not changed by 17β-estradiol treatment. 
The AQP5 mRNA expression did not change as a result of tamoxifen citrate pretreatment on the 
investigated days (Figure 2A). In contrast, the level of AQP5 protein increased on day 18 (p < 0.0124), 
but did not change on the last day of pregnancy, compared to the control (Figure 2B). 
Figure 2. Results of PCR and Western immunoblotting experiments after tamoxifen treatment. The 
changes of mRNA (A) and protein (B) expression of AQP5 after tamoxifen citrate (T) pretreatment in 
pregnant rat uterus on days 18 and 22. ns > 0.05, * p < 0.05 as compared with the data on non-treated 
control uterus. Each bar denotes the mean ± S.D. n = 6. The bands resulting from non-specific bindings 
of the polyclonal AQP5-antibody were not changed by tamoxifen treatment. 
Figure 1. Results of PCR and estern immunoblotting experiments after 17β-estradiol treatment.
The changes of mRNA (A) and protein (B) expression of aquaporin 5 (AQP5) after 17β-estradiol (E)
pretreatment in pregnant rat uterus on days 18 and 22. ns > 0.05, *** p < 0.001 as compared with the
data on non-treated control uterus. Each bar denotes the mean ˘ S.D. n = 6. The bands resulting from
non-specific bindings of the polyclonal AQP5-antibody were not changed by 17β-estradiol treatment.
The AQP5 mRNA expressio did not c ange as a result of amoxif n citrate pretreatment on the
investigated days (Figure 2A). In contrast, the level of AQP5 protei increased on day 18 (p < 0.0124),
but did not change on the last day of pregnancy, compared to the control (Figure 2B).
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Figure 2. Results of PCR and Western immunoblotting experiments after tamoxifen treatment.
The hanges of mRNA (A) and protein (B) expression of AQP5 after tamoxifen citrate (T) pretreatment
in pregnant rat uterus on d ys 18 and 22. ns > 0.05, * p < 0.05 as compared with the data on non-treated
control uterus. Each bar denotes the mean˘ S.D. n = 6. The bands resulting from non-specific bindings
of the polyclonal AQP5-antibody were not changed by tamoxifen treatment.
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Clomiphene citrate pretreatment did not cause any significant changes in the AQP5 mRNA
(Figure 3A) and protein (Figure 3B) levels on day 18 and day 22 of pregnancy, compared to the control.
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Figure 3. Results of PCR and Western immunoblotting experiments after clomiphene citrate treatment.
The changes of mRNA (A) and protein (B) expression of AQP5 after clomiphene citrate (C) pretreatment
in pregnant rat uterus on days 18 and 22. ns > 0.05 as compared with the data on non-treated control
uterus. Each bar denotes the mean ˘ S.D. n = 6. The bands resulting from non-specific bindings of the
polyclonal AQP5-antibody were not changed by clomiphene citrate treatment.
2.2. The Effects of Gestagen-Related Compounds on AQP5 Expression
Progesterone, levonorgestrel, and medroxyprogesterone acetate pretreatment caused a significant
increase in AQP5 mRNA and protein levels both on day 18 (p < 0.001) and day 22 (p < 0.001) of
pregnancy (Figures 4–6).
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uterus. Each bar denotes the mean ± S.D. n = 6. The bands resulting from non-specific bindings of the 
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Figure 5. Results of PCR and Western immunoblotting experiments after levonorgestrel treatment. 
The changes of mRNA (A) and protein (B) expression of AQP5 after levonorgestrel (L) pretreatment 
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Figure 4. Results of PCR and Western immunoblotting experiments after progesterone treatment.
The changes of mRNA (A) and protein (B) expression of AQP5 after progesterone (P) pretreatment in
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Figure 5. Results of PCR and Western immunoblotting experiments after levonorgestrel treatment.
The changes of mRNA (A) and protein (B) expression of AQP5 after levonorgestrel (L) pretreatment in
pregnant rat uterus on days 18 and 22. *** p < 0.001 as compared with the data on non-treated control
uterus. Each bar denotes the mean ˘ S.D. n = 6. The bands resulting from non-specific bindings of the
polyclonal AQP5-antibody were not changed by levonorgestrel treatments.
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2.3. The Effect of Hormonally-Induced Preterm Delivery on AQP5 Expression 
In the hormonally-induced preterm delivery model, a significant decrease of AQP5 mRNA and 
protein levels was caused on day 20 of pregnancy, compared to the non-treated animals on pregnancy 
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Figure 6. Results of PCR and Western immunoblotting experiments after medroxyprogesterone acetate
treatment. The changes of mRNA (A) and protein (B) expression of AQP5 after medroxyprogesterone
acetate (MPA) pretreatment in pregnant rat uterus on days 18 and 22. *** p < 0.001 as compared with
the data on non-treated control uterus. Each bar denotes the mean ˘ S.D. n = 6. The bands resulting
from non-specific bindings of the olyclonal AQP5-antibody were not changed by MPA treatments.
2.3. The Effect of Hormonally-Induced Preterm Delivery on AQP5 Expression
In the hormonally-induced preterm delivery model, a significant decrease of AQP5 mRNA and
protein levels was caused on day 20 of pregnancy, compared to the non-treated animals on pregnancy
day 20 (p < 0.001). This decrease in AQP5 expression was similar to the last day of pregnancy (Figure 7).
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a strong correlation between mRNA and protein expression [30]. We suppose that estrogen may
increase the stability of AQP5 protein without alteration of mRNA expression, and that this process
can lead to the increase in protein expression.
In our study, 17β-estradiol pretreatment did not cause any changes in the AQP5 mRNA expression,
but the amount of AQP5 protein was significantly increased, both on day 18 and day 22 of pregnancy.
In view of this, it appears that estrogen has a significant effect on AQP5 protein expression in the
late-pregnant rat uterus.
Tamoxifen citrate is a nonsteroidal triphenylethylene derivative with a selective estrogen receptor
modulator effect. This means that tamoxifen acts like antiestrogen in breast but estrogen agonist
in bone and uterus, and it is used in the treatment of certain estrogen-dependent breast cancer [31].
In the case of tamoxifen citrate, there was a significant increase in the amount of AQP5 protein on day
18 of pregnancy.
Clomiphene citrate is a nonsteroidal drug which also has selective estrogen receptor modulator
effects. It consists of two isomers which have mixed estrogenic and antiestrogenic effects, and these
features depend on the target tissue [32]. Clomiphene citrate did not cause any changes either in the
AQP5 mRNA expression or in the AQP5 protein amount. We suppose that clomiphene could not exert
its effect on the hypothalamic-pituitary axis during the four-day-long pretreatment.
There are different types of animal models for preterm birth, since preterm delivery could
have various pathophysiological backgrounds. We used a hormonally-induced model to prove the
progesterone effect on AQP5 expression. Preterm delivery was induced by antigestagen mifepristone
and prostaglandin E2. Mifepristone induces preterm delivery by blocking the progesterone
receptor [33]. Prostaglandin E2 contributes to cervical ripening and the induction of labor [34]. In this
model, day 20 was the starting day of preterm birth. We found a marked decrease of AQP5 mRNA and
protein levels on day 20, and this change in AQP5 expression was similar to the last day (day 22) of
gestation. The explanation for this phenomenon could be that in the preterm delivery, the progesterone
level decreases significantly, followed by the reduction of AQP5 expression.
In summary, we can conclude that AQP5 expression is influenced by both female hormones
with progesterone predominance in the late-pregnant rat uterus. Our preterm birth model studies
suggest that the lack of progesterone effect leads to reduced AQP5 expression and may contribute to
the initiation of preterm labor.
4. Materials and Methods
4.1. Experimental Animals
4.1.1. Housing and Handling of the Animals
The animals were treated in accordance with the European Communities Council Directive
(86/609/ECC) and the Hungarian Act for the Protection of Animals in Research (Article 32 of Act
XXVIII), and all experiments involving animal subjects were carried out with the approval of the
Hungarian Ethical Committee for Animal Research (permission number: IV/198/2013).
Sprague-Dawley rats (INNOVO Ltd., Gödöllo˝, Hungary) were kept at a controlled temperature
of 20–23 ˝C, in relative humidity of 40%–60% and under a 12 h light/dark cycle. The animals were fed
a standard rodent pellet diet (INNOVO Ltd., Isaszeg, Hungary), with tap water available ad libitum.
4.1.2. Mating of the Animals
Mature female Sprague-Dawley rats (180–200 g) in estrus were collected. The vaginal impedance
was measured by an Estrus Cycle Monitor EC40 (Fine Science Tools, Foster City, CA, USA).
The appropriate female and male rats (240–260 g) were mated in a special mating cage. In this
cage there was a time-controlled movable metal door separating the rats of different sex. Since rats are
usually active at night, the separating door was opened in the early morning hours. Four or five hours
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after the potential copulation, vaginal smears were taken from the female rats and were examined by
a microscope at a 1200ˆmagnification. The presence of a copulation plug or the presence of sperm in
the native vaginal smear was accepted as proof of the mating. These female animals were separated
and regarded as first-day pregnant rats [22,35].
4.2. In Vivo Treatments of the Rats
The 17β-estradiol valerate, tamoxifen citrate, and clomiphene citrate (Sigma-Aldrich, Budapest,
Hungary) pretreatment of the pregnant animals was started on day 14 and day 18 of pregnancy.
The compounds were dissolved in olive oil. The animals were injected subcutaneously with
1 µg/0.1 mL of 17β-estradiol [35,36], 5 mg/0.1 mL of tamoxifen citrate [37], and 1 mg/0.1 mL of
clomiphene citrate [38,39] once a day for four days. On day 18 and 22, the uterine samples were
collected and the molecular studies were carried out.
The progesterone, levonorgestrel, and medroxyprogesterone acetate (Sigma-Aldrich) pretreatment
of the pregnant animals was started on day 11 and 15 of pregnancy. These hormones were dissolved in
olive oil and injected subcutaneously every day in a dose of 0.5 mg/0.1 mL of progesterone [35,36] and
levonorgestrel [40], and 5 mg/0.1 mL of medroxyprogesterone acetate [41] for seven days. On day 18
and 22, the uterine samples were collected, and the molecular studies were carried out. The duration
of the hormonal treatments were determined based on our earlier studies [35,42,43].
The preterm delivery group was treated with mifepristone (Sigma-Aldrich), which was dissolved
in olive oil and given subcutaneously in a dosage of 3 mg/0.1 mL on day 19 of pregnancy at 9 A.M. On the
same day at 4 P.M., the animals received intravaginal prostaglandin E2 at a dose of 0.5 mg/mL [44].
The preterm birth occurred on the following day (day 20 of pregnancy). Uterine samples were collected
after the beginning of the preterm birth, and molecular studies were carried out.
4.3. RT-PCR Studies
4.3.1. Tissue Isolation
The rats (250–300 g) were sacrificed by CO2 inhalation. Newborn rats were sacrificed by immediate
cervical dislocation. The uterine tissues from pregnant animals (n = 6) (tissue between two implantation
sites) were rapidly removed and placed into RNAlater Solution (Sigma-Aldrich). The tissues were
frozen in liquid nitrogen and stored at ´75 ˝C until the extraction of total RNA.
4.3.2. Total RNA Preparation
Total cellular RNA was isolated by extraction with guanidinium thiocyanate-acid-phenol-
chloroform according to the procedure of Chomczynski and Sacchi [45]. After precipitation
with isopropanol, the RNA was washed with 75% ethanol and then re-suspended in diethyl
pyrocarbonate-treated water. RNA purity was controlled at an optical density of 260/280 nm with
BioSpec Nano (Shimadzu, Kyoto, Japan); all samples exhibited an absorbance ratio in the range of
1.6–2.0. RNA quality and integrity were assessed by agarose gel electrophoresis.
4.3.3. Real-Time Quantitative Reverse-Transcriptase PCR
Reverse transcription and amplification of the PCR products were performed by using the TaqMan
RNA-to-CT-Step One Kit (Life Technologies, Budapest, Hungary) and an ABI StepOne Real-Time
cycler. Reverse-transcriptase PCR amplifications were performed as follows: 48 ˝C for 15 min and
95 ˝C for 10 min, followed by 40 cycles at 95 ˝C for 15 s and 60 ˝C for 1 min. The samples of qPCR
experiments contained “no-template” control, “absolute” control or RNA samples from non-treated
and treated uterus. The generation of specific PCR products was confirmed by melting curve analysis.
Table 1 contains the assay IDs for the primers used and the reaction parameters. All samples were
run in triplicate. The fluorescence intensities of the probes were plotted against PCR cycle number.
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The amplification cycle displaying the first significant increase of the fluorescence signal was defined
as the threshold cycle (Ct).
Table 1. Parameters of the applied primers and PCR reactions. The real-time reverse transcription
polymerase chain reactions were used to determine the changes in mRNA expression. In our studies, the
parameters of inventoried TaqMan assays were defined by Life Technologies (ThermoFisher Scientific,
Budapest, Hungary).
TaqMan
Assays
Assay ID (ThermoFisher
Scientific)
Accession
Number
Assay
Location
Amplicon
Length
Annealing
Temp. (˝C)
Reaction
Volume (µL)
AQP5 Rn00562837_m1 NM_012779.1 473 69 60 20
β-Actin Rn00667869_m1 NM_031144.3 881 91 60 20
4.4. Western Blot Analysis
The uterine tissues from pregnant animals (tissue between two implantation sites) were
homogenized using a Micro-Dismembrator (Sartorius AG, Goettingen, Germany) and centrifuged at
5000ˆ g for 15 min at 4 ˝C in RIPA Lysis Buffer System (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), which contains phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate, and protease
inhibitor cocktail. Total protein amounts from supernatant were determined with spectrophotometry
(BioSpec-nano, Shimadzu, Japan).
Twenty-five micrograms of sample protein per well was subjected to electrophoresis on 4%–12%
NuPAGE Bis-Tris Gel in XCell SureLock Mini-Cell Units (Life Technologies). Proteins were transferred
from gels to nitrocellulose membranes using the iBlot Gel Transfer System (Life Technologies).
The Ponceau S (Sigma-Aldrich) was used to check the standard running and transfer conditions.
The blots were incubated overnight on a shaker with AQP5 (35 kDa) and β-actin (43 kDa) polyclonal
antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX, USA, diluted 1:200, host: rabbit, specificity:
mouse, rat and human) in blocking buffer. Antibody binding was detected with the Western Breeze®
Chromogenic immunodetection kit (ThermoFisher Scientific. The AQP5 antibody reacted to several
bands, including a band at the size of AQP5 (43 kDa). The bands resulting from non-specific bindings
of the polyclonal AQP5-antibody were not changed by hormonal or drug treatments.
Images were captured with the EDAS290 imaging system (Csertex Ltd., Budapest, Hungary),
and the optical density of each immunoreactive band was determined with Kodak 1D Images
analysis software. The β-actin was used for protein normalization for this semi-quantitative methods.
Optical densities were calculated as arbitrary units after local area background subtraction.
4.5. Statistical Analysis
All experiments were carried out on six animals, and the molecular biology studies were repeated
three times. Statistical analyses were performed using Prism 5.0 software (Graph Pad Software, Inc.,
San Diego, CA, USA). ANOVA Dunnett test or two-tailed unpaired t test were used. p < 0.05 was
considered as a level of significance.
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